GREENVILLE – RFPI, which in early 2019 secured FDA clearance for its new blood flow and perfusion imaging device and now has turned that news into $2 million of new investment capital.

According to a securities filing, the company also wants another $5 million.

Two investors have participated in the fundraiser so far.

The company, which was bootstrapped with a loan from the North Carolina Biotechnology Center, was granted FDA approval to begin marketing its iCertaintydevice in January of 2019.

The FDA’s 510(k) clearance, permitting medical device marketing, lets RFPi sell the iCertainty to surgeons for use in open surgery procedures.

RFPi’s proprietary product, based on technology developed at, and licensed from, East Carolina University, shows real-time blood flow and perfusion in vascular structures and critical tissues during surgeries. iCertainty is the first commercially available imaging device that doesn’t require traditional modalities such as injections, dyes, radiation, direct patient contact, or interrupting a surgical procedure for X-ray, ultrasound or MRI.

It has the potential to reduce complications, repeat surgeries and costs, and to improve clinical outcomes.

NCBiotech awarded a $250,000 Small Business Research Loan to RFPi in 2017 to help the company develop a prototype device. RFPi videos on the company website show how the iCertainty works.

(The NCBiotech Center contributed to this story.)

Greenville’s RFPi receives FDA OK for surgical device